RBC Capital Reiterates Outperform on Legend Biotech, Maintains $86 Price Target
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Leonid Timashev has reiterated an Outperform rating on Legend Biotech (NASDAQ:LEGN) and maintained a price target of $86.
June 21, 2024 | 2:24 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
RBC Capital analyst Leonid Timashev has reiterated an Outperform rating on Legend Biotech (NASDAQ:LEGN) and maintained a price target of $86.
The reiteration of an Outperform rating and the maintenance of a high price target by a reputable analyst can boost investor confidence in Legend Biotech, likely leading to a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100